Source: International Congress 2014 – Asthma and COPD devices and treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kuttler, T. Dimke (Basel, Switzerland). Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model. Eur Respir J 2014; 44: Suppl. 58, 913

Member's Comments

No comment yet.

Related content which might interest you: Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015 LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices Source: International Congress 2014 – Innovative technology and techniques in respiratory function Year: 2014 Are ultrafine particle inhalers, better for patients with small airway involvement? Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Reproducibility of inhaler use and pulmonary drug deposition in COPD Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 A novel biophysical simulation model predicts consistent lung delivery of QVA149, glycopyrronium and indacaterol via the Breezhaler® device Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Pulmonary response to salbutamol inhalation using dynamic OE-MRI in patients with asthma Source: Annual Congress 2013 –The different modalities for current imaging and for future issues Year: 2013 B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD Source: International Congress 2016 – Airway biomarkers Year: 2016 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Dose-response effect of small particle vs standard size particle inhaled corticosteroids on severe asthma exacerbations by sex Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013